Premium
Understanding and addressing hepatitis C reinfection in the oral direct‐acting antiviral era
Author(s) -
FaladeNwulia O.,
Sulkowski M. S.,
Merkow A.,
Latkin C.,
Mehta S. H.
Publication year - 2018
Publication title -
journal of viral hepatitis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 100
eISSN - 1365-2893
pISSN - 1352-0504
DOI - 10.1111/jvh.12859
Subject(s) - men who have sex with men , hepatitis c , medicine , hepatitis c virus , human immunodeficiency virus (hiv) , population , psychological intervention , virology , optimism , immunology , antiviral therapy , environmental health , chronic hepatitis , virus , psychology , syphilis , psychiatry , social psychology
Summary The availability of effective, simple, well‐tolerated oral direct‐acting antiviral ( DAA ) hepatitis C regimens has raised optimism for hepatitis C virus ( HCV ) elimination at the population level. HCV reinfection in key populations such as people who inject drugs ( PWID ) and HIV ‐infected men who have sex with men ( MSM ) however threatens the achievement of this goal from a patient, provider and population perspective. The goal of this review was to synthesize our current understanding of estimated rates and factors associated with HCV reinfection. This review also proposes interventions to aid understanding of and reduce hepatitis C reinfection among PWID and HIV ‐infected MSM in the oral direct‐acting antiviral era.